title: [Inhibitors of the receptor A for endothelin-1].
abstract: Endothelin-1 (ET-1) is a vasoactive peptide but also mitogenic and pro-angiogenic. ET-1 exerts its actions via two G protein-coupled receptors, ETA and ETB. ET-1 is involved in the progression of prostate cancer. Its actions affect the tumor cell proliferation, inhibition of apoptosis, angiogenesis, migration, invasion, metastasis to the bone growth. Inhibitors of receptors of ET-1 in clinical development are the atrasentan and ZD4054. This article reports on controlled, randomized, phase II and III studies on this new therapeutic class.
authors.affiliation: Service d'urologie, Hôpital Huriez, CHRU Lille, 1 place de Verdun Lille cedex, France. arnauld.villers@wanadoo.fr
authors.forename: A
authors.initials: A
authors.lastname: Villers
authors.forename: Y
authors.initials: Y
authors.lastname: Neuzillet
authors.forename: P
authors.initials: P
authors.lastname: Beuzeboc
mesh_terms: D000077868:Atrasentan; D065130:Endothelin A Receptor Antagonists; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011759:Pyrrolidines / Q000627:therapeutic use*
chemical_list: D065130:Endothelin A Receptor Antagonists; D011759:Pyrrolidines; C511404:ZD4054; D000077868:Atrasentan